Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celtic Therapeutics Earmarks $50M For ADC Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

Private equity firm Celtic Therapeutics is promising a $50 million investment in ADC Therapeutics, a new company that will work closely with Celtic’s other investment Spirogen on antibody-drug conjugates.

You may also be interested in...



Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation

Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.

ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie

The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel